24 May 2023 | Wednesday | News
From Left to Right: Bernard Birkett, Senior Vice President, Chief Financial and Operations Officer; Marcus Tang, Senior Director, Operations, Jurong; Eric Green, President, CEO and Chair of the Board of Directors; Goh Wan Yee, SVP and Head of Healthcare, EDB; and Alagu Subramaniam, Senior Director, Sales and Commercial Operations, Asia Pacific at the inauguration ceremony of West's upgraded manufacturing facility in Singapore
West Pharmaceutical Services, Inc. (West), a global leader in innovative solutions for injectable drug administration, today inaugurates its newly advanced manufacturing facility in Jurong, Singapore. This is part of West’s commitment to invest more than US$350 million globally in 2023, with the majority used to expand capacity and deliver on demand of drug customers for the West’s products and services, and to meet the growing needs of customers to support sensitive and complex molecules and the changing regulatory environment.
The Jurong facility investment comes at a critical time as the advancement of biologics is reshaping the way many diseases are prevented, diagnosed, and treated. This facility investment enables West to serve its customers’ requirements by providing high-quality containment products for injectable drugs at one location, from start to finish, in the Asia Pacific region, helping to reduce overall lead times for customers.
Capacity and capabilities expansion for future demand
With West's robust capital expansion program, the 18,000-square-meter Jurong facility is now equipped with industry-leading coating, pharmaceutical washing, sterilization and automated vision inspection capabilities for elastomers. This minimizes the risk of potential contamination and compatibility issues with packaging components. In addition, new molding and compounding equipment have been installed with improved energy efficiency and automation capabilities.
West’s Jurong facility now has the capabilities to manufacture a full range of advanced containment products, such as components having Westar™ Select quality level, Envision™ verification process, and FluroTec™ barrier film, to meet the healthcare industry’s growing focus on biologics, including cell and gene therapeutics, while providing customers with stronger on the-ground technical support. It will also support Singapore in achieving a complete supply chain manufacturing capability for future vaccine response.
West continues on its journey to be more sustainable
In line with West’s overall focus and continued commitment to sustainability, the company installed an eco-friendly cooling tower control system to optimize energy at the facility. This new system will result in total energy savings of 281,772 Kwh and a reduction of 115 tons of CO2 emissions annually. A feasibility study is also under way to install solar panels on the rooftop of the facility.
Eric Green, President, CEO, and Chair of the Board of Directors, West, said, “This year, West celebrates a major milestone - its 100th anniversary. As we embark on the next century of scientific innovation, we look forward to strengthening our global networks to meet the needs of the growing critical changes in healthcare and drug delivery. This investment in our Jurong facility will continue to play a critical role in fulfilling our purpose of providing customers and their patients access to medicines globally.”
Goh Wan Yee, SVP and Head of Healthcare, EDB said, “We would like to congratulate West on the inauguration of its newly advanced manufacturing facility and its 40th anniversary in Singapore. West’s continued investments in Singapore is testament to the strong base of talent, innovation, and manufacturing capabilities in the biomedical sciences ecosystem, as well as Singapore’s hub status for the Asia Pacific market. We look forward to strengthening our long-
term partnership with West, supporting its continued growth to drive better healthcare outcomes, and creating good job opportunities for Singaporeans.”
West employs more than 600 people across three locations in Singapore - the JTC Summit Office, the Jurong plant, and the Gemini laboratory. To date, over 200 new jobs have been created as part of the investment and approximately 40 additional roles are expected to be added by the end of 2023.